Kellner Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Kellner Capital’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.3M	Buy	+4,100	New	+$797K	2.34%	14

Other funds holding KRTX

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Kellner Capital's KRTX Position: Q4 2023 in Review

Kellner Capital opened a new position in Karuna Therapeutics, Inc. Common Stock (KRTX) in Q4 2023: 4,100 shares worth $1.3M. The stake represents 2.34% of the portfolio and ranks #14 among its holdings.

328 funds tracked by Wall St. Rank hold KRTX as of Q4 2023.

Kellner Capital held 4,100 shares of Karuna Therapeutics, Inc. Common Stock worth $1.3M as of Q4 2023.
Karuna Therapeutics, Inc. Common Stock was a new Kellner Capital position in Q4 2023.
Karuna Therapeutics, Inc. Common Stock made up 2.34% of Kellner Capital's portfolio in Q4 2023, its #14 holding.
328 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Kellner Capital's 13F filing for Q4 2023, filed 7 Feb 2024.